Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026, creating a fully integrated global biosimilars leader. Amneal LLC paid $375 million in cash and issued approximately 28.94 million shares of Class A common stock to the sellers. The transaction includes up to $350 million in contingent regulatory milestone payments and potential royalties based on gross profit hurdles. To fund the acquisition, Amneal LLC secured a $350 million incremental term loan under an amendment to its existing credit agreement. This strategic combination integrates Kashiv’s biologics R&D and manufacturing capabilities with Amneal’s commercial scale, positioning the company to capitalize on upcoming biologic loss-of-exclusivity events. Amneal Pharmaceuticals is a diversified global biopharmaceutical company focused on affordable generic, specialty, and biosimilar medicines.
